1-9 of 9
Stephen T. Keir
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma

Available to Purchase
Humeyra Kaanoglu, Adebimpe Adefolaju, Casey Fraley, Mariah Shobande, Rajaneekar Dasari, Breanna Mann, Noah Bell, Stephen T. Keir, Dominique Higgins, David E. Kram, Shawn D. Hingtgen, Aziz Sancar, Andrew B. Satterlee
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF13.
https://doi.org/10.1158/1535-7163.MCT-24-1098
Published: 15 April 2025
View articletitled, Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
Open the PDF for Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408).

Free
C. Patrick Reynolds, Min H. Kang, Hernan Carol, Richard B. Lock, Richard Gorlick, E. Anders Kolb, Denise Alexander, Raushan T. Kurmasheva, Stephen T. Keir, John M. Maris, Jianrong Wu, Peter J. Houghton, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C106.
https://doi.org/10.1158/1535-7163.TARG-11-C106
Published: 12 November 2011
View articletitled, Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408).
Journal Articles

Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine.

Free
Peter J. Houghton, John M. Maris, Stephen T. Keir, Richard B. Lock, Hernan Carol, Richard Gorlick, E. Anders Kolb, Min H. Kang, C. Patrick Reynolds, Raushan T. Kurmasheva, Kathleen R. Whiteman, Malcolm Anders Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C105.
https://doi.org/10.1158/1535-7163.TARG-11-C105
Published: 12 November 2011
View articletitled, Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine.
Journal Articles

Abstract C103: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias.

Free
Malcolm A. Smith, Min H. Kang, Christopher Patrick Reynolds, Richard B. Lock, Hernan Carol, Richard Gorlick, E. Anders Kolb, John M. Maris, Stephen T. Keir, Catherine A. Billups, Raushan T. Kurmasheva, Peter J. Houghton
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C103.
https://doi.org/10.1158/1535-7163.TARG-11-C103
Published: 12 November 2011
View articletitled, Abstract C103: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias.
Journal Articles

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

Free
Peter J. Houghton, Christopher L. Morton, Richard Gorlick, Richard B. Lock, Hernan Carol, C. Patrick Reynolds, Min H. Kang, John M. Maris, Stephen T. Keir, E. Anders Kolb, Jianrong Wu, Amy W. Wozniak, Catherine A. Billups, Larry Rubinstein, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 101–112.
https://doi.org/10.1158/1535-7163.MCT-09-0952
Published: 12 January 2010
View articletitled, Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program
Open the PDF for Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program in another window
Includes: Supplementary data
Journal Articles

Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase

Free
Peter J. Houghton, John M. Maris, Josh Courtright, Henry S. Friedman, Stephen T. Keir, Richard B. Lock, Hernan Carol, E. Anders Kolb, Richard Gorlick, Min Kang, C. Patrick Reynolds, Christopher L. Morton, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C57.
https://doi.org/10.1158/1535-7163.TARG-09-C57
Published: 10 December 2009
View articletitled, Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase
Journal Articles

The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion

Free
Anita B. Hjelmeland, Kathryn P. Lattimore, Brian E. Fee, Qing Shi, Sarah Wickman, Stephen T. Keir, Mark D. Hjelmeland, David Batt, Darell D. Bigner, Henry S. Friedman, Jeremy N. Rich
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (9): 2449–2457.
https://doi.org/10.1158/1535-7163.MCT-07-0155
Published: 17 September 2007
View articletitled, The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion
Open the PDF for The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion in another window
Journal Articles

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft

Free
C. Lynn Cheng, Stewart P. Johnson, Stephen T. Keir, Jennifer A. Quinn, Francis Ali-Osman, Csaba Szabo, Hongshan Li, Andrew L. Salzman, M. Eileen Dolan, Paul Modrich, Darell D. Bigner, Henry S. Friedman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (9): 1364–1368.
https://doi.org/10.1158/1535-7163.MCT-05-0128
Published: 16 September 2005
View articletitled, Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft
Open the PDF for Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft in another window
Journal Articles

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition

Free
Ranjit K. Goudar, Qing Shi, Mark D. Hjelmeland, Stephen T. Keir, Roger E. McLendon, Carol J. Wikstrand, Elizabeth D. Reese, Charles A. Conrad, Peter Traxler, Heidi A. Lane, David A. Reardon, Webster K. Cavenee, Xiao-Fan Wang, Darell D. Bigner, Henry S. Friedman, Jeremy N. Rich
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (1): 101–112.
https://doi.org/10.1158/1535-7163.101.4.1
Published: 18 January 2005
View articletitled, Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
Open the PDF for Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition in another window